SQZ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 jul 2023 @ 19:00):

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions...

Stats
Dagens volum	30.14M
Gjennomsnittsvolum	553 611
Markedsverdi	12.83M
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.201
ATR14	$0.0350 (68.86%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-14	Vink Patrick V.j.j.	Buy	39 875	Stock Option
2023-06-14	Srivastava Sapna	Buy	39 875	Stock Option
2023-06-14	Schulman Amy W	Buy	39 875	Stock Option
2023-06-14	Schegerin Marc	Buy	39 875	Common Stock
2023-06-14	Jensen Klavs F.	Buy	39 875	Stock Option

INSIDER POWER
99.96
Last 97 transactions
Buy: 14 673 100 \| Sell: 2 196 730

Volum Korrelasjon

Lang: 0.00 (neutral)

Kort: -0.22 (neutral)

Signal:(30.626) Neutral

SQZ Biotechnologies Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

SQZ Biotechnologies Korrelasjon - Valuta/Råvare

0.15
( neutral )

-0.62
( weak negative )

0.00
( neutral )

-0.07
( neutral )

0.34
( neutral )

-0.21
( neutral )

SQZ Biotechnologies Økonomi

Annual	2022
Omsetning:	$21.03M
Bruttogevinst:	$21.03M (100.00 %)
EPS:	$-2.72

FY	2022
Omsetning:	$21.03M
Bruttogevinst:	$21.03M (100.00 %)
EPS:	$-2.72

FY	2021
Omsetning:	$27.10M
Bruttogevinst:	$27.10M (100.00 %)
EPS:	$-2.45

FY	2020
Omsetning:	$21.00M
Bruttogevinst:	$21.00M (100.00 %)
EPS:	$-9.35

Financial Reports:

No articles found.

SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.